We are a clinical stage artificial intelligence, or AI, company specializing in improving diagnostic accuracy through deep learning technology, an advanced form of AI. Our AI platform and AI-based decision making support tools are designed to interpret and analyze a broad range of patient dataconcurrently with 3D medical images. Our goal is to provide physicians with tools to achieve a better differential diagnosis, which we believe will ultimately improve patient outcomes and significantly decrease the total cost of care. Artificial intelligence is a broad term generally used to describe a situation when a machine mimics “cognitive” functions that humans associate with human intelligence, such as “learning” and “problem solving. Basic artificial intelligence includes machine learning, where a machine uses algorithms to parse data, learn from it, and then make a determination or prediction about something in the world. The machine is “trained” using large amounts of data and algorithms that give it the ability to learn how to perform the task. Deep learning is part of a family of machine learning methods based on learning data representations, as opposed to task-specific algorithms. The global diagnostics market is driven in large part by solutions that can be applied in acute care settings, as these tools will drive decisions regarding hospital admissions and the associated spend. However, despite advances in medical imaging and other diagnostic tools, misdiagnosis remains a common occurrence, and payors in the U.S. and other healthcare systems are increasingly refusing to pay for the cost of care that is the result of misdiagnosis.1 We believe that improved diagnoses and outcomes are achievable through the adoption of AI-based decision making tools. Our initial focus is on the development of diagnostic solutions for the emergency room and acute care space utilizing our proprietary AI platform. The platform is designed to interpret and analyze medical images concurrently and in conjunction with other patient data, such as age, co-morbidities, medical history, genomic information and laboratory test results to provide decision making support for the attending physician. Using deep learning technology, the platform is capable of continuous learning which improves its performance with increased use and physician feedback. The result will provide the physician with an assessment of the patient for use in guiding diagnosis and care. Our initial family of products, Accipio, utilizes machine vision and deep learning technologies to create software tools that help physicians identify or rule out intracranial hemorrhage, or ICH, typically caused by stroke or head trauma. Accipio analyzes non-contrast head computer tomography, or CT, images using algorithms which identify and annotate potential regions of interest, or ROI, consistent with acute ICH. To date, we have not generated any revenues. In May 2018, our AccipioIx product received CE mark approval. None of our other products have been approved for commercial sale by regulatory authorities. We will not be able to generate revenues for our other products, or generate revenues for any products in the United States, until we obtain those approvals. We have experienced net losses since our inception and had net losses of $9.2 and $1.9 million in fiscal year 2017 and in the first quarter of 2018, respectively. Our auditors have expressed doubt about our ability to continue as a going concern unless we are able to raise equity or debt financing. Our Accipio products are designed to be easily integrated with most existing medical imaging workflow platforms and to be used with many existing standards-based medical imaging technologies, including CT, magnetic resonance imaging, or MRI, and ultrasound. The Accipio family of products includes the following suite of diagnostic software solutions: . AccipioDx is a high-accuracy diagnostic utility intended to support physicians in ruling out ICH in acute settings, supplementing the standard clinical tools available to the treating physician; (A) L Berlin. Radiologic errors, past, present and future. L Berlin. Diagnosis, 2014; 1(1): 79–84 (B) S Burwell. Setting Value-Based Payment Goals — HHS Efforts to Improve U.S. Health Care. N Engl J Med 2015; 372:897-899 . AccipioIx provides (i) workflow prioritization in the picture archiving and communication systems, or PACS, worklist, (ii) case-level signaling of a potential ICH to a reader and/or (iii) case-level signaling of a potential ICH and ROI location(s) to PACS or a reader; and . AccipioAx creates a duplicate, annotated series of images, as well as a full 3D image rendering of the brain, which supplements the original, unaltered CT scans. AccipioAx is intended to assist clinicians in interpreting CT examinations of the head by highlighting specific ROIs for identification and further analysis of ICH. To date, we have entered into agreements with GE Healthcare and IBM Watson Health, two leading radiology original equipment manufacturers, or OEMs, to integrate our products into their radiology software and hardware platforms. The OEMs’ commercial obligations under the agreements commence upon our receiving regulatory approval for the products. In addition, we have entered into an agreement with Samsung Neurologica to collaborate regarding the integration of our applications into portable Samsung Neurologica CereTom® CT scanners used in intensive care units, or ICUs, and mobile stroke units, or MSUs. We have also entered into an agreement with Intel Corporation to optimize our artificial intelligence technology. We believe that by leveraging the existing sales and marketing infrastructure of these channel partners, each of which is a leading medical equipment manufacturer, we will be able to achieve high market penetration and user adoption rates. We recently received designation under the Expedited Access Pathway, which under the 21st Century Cures Act was converted to Breakthrough Device Program, or Breakthrough, from the U.S. Food and Drug Administration, or the FDA, for AccipioDx. The Breakthrough program is intended to reduce the time associated with product development by promoting earlier and more interactive engagement with the FDA staff during the development and review of medical devices. The FDA designated AccipioDx for Breakthrough based on a proposed indication for use in acute ICH diagnoses. The FDA has stated that it does not intend to grant more than a single Breakthrough designation for a given indication. We have not submitted any Accipio products for FDA approval, but we intend to do so commencing in the third quarter of 2018. We expect to receive FDA approval for AccipioIx during the fourth quarter of 2018, and we expect to receive FDA approval for AccipioDx as well as AccipioAx in 2019. We were granted ISO 13485 certification and received CE mark approval for AccipioIx in May 2018. We expect CE mark approvals for AccipioAx and Dx in the first half of 2019. There is no assurance that the FDA will clear any Accipio products for distribution or sale, or that CE marks will be obtained for products which have not yet received it. --- We were incorporated on October 2, 2013 as an Israeli limited company. Our principal executive office is located at 76 Yigal Alon Street, 5th Floor, Tel Aviv, Israel 6706701. Our telephone number is +972-3 620 0028. Our website address is www.maxq.ai.